FIELD: virology.
SUBSTANCE: invention relates to virology. The vaccine strain B/60/Hong Kong/2017/5584 (Victoria line) is presented - a reassortant obtained by crossing the "wild" virus B/Hong Kong/286/2017 (Victoria line) with a cold-adapted temperature-sensitive virus B/USSR/60/69 - a donor attenuation, harmless to humans. The strain actively reproduces in developing chicken embryos at an optimal temperature of 32°С, is characterized by cold adaptation and temperature sensitivity, as well as harmlessness to laboratory animals. The reassortant inherited the genes encoding the virus surface antigens, hemagglutinin (HA) and neuraminidase (NA), from the epidemic parental virus, and the remaining six genes encoding internal and non-structural proteins from the attenuation donor. Thus, the vaccine strain B/60/Hong Kong/2017/5584 (Victoria line), in terms of the main biological properties studied in preclinical in vitro and in vivo experiments, meets the requirements for vaccine strains by Pharmacopoeia Monograph (FSP: Р N003224/01-270313) on Ultravak®, a live allantoic influenza vaccine for intranasal use for adults and children.
EFFECT: invention can be used in healthcare for the prevention of the incidence of influenza among adults and children using a live influenza intranasal vaccine from the influenza virus strain B/60/ Hong Kong/2017/5584 (Victoria line) in the case of spread in the human population of similar influenza viruses.
1 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| REASSORTANT STRAIN OF INFLUENZA VIRUS B/60/WASHINGTON/2019/3676 (VICTORIA LINE) FOR THE PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2021 |
|
RU2757397C1 |
| VACCINE STRAIN OF INFLUENZA B/60/COLORADO/2017/1 (VICTORIA LINE) FOR THE PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2746274C2 |
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/HONGKONG/2017/75108 (H7N9) FOR PRODUCING POTENTIALLY PANDEMIC LIVE INTRANASAL INFLUENZA VACCINE | 2018 |
|
RU2685121C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/HONG KONG/2019/2573 (H3N2) FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783894C1 |
| VACCINE INFLUENZA VIRUS STRAIN A/17/HONGKONG/2014/8296 (H3N2) FOR PREPARING LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2016 |
|
RU2606019C1 |
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/BRISBANE/2017/7178 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2711101C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA VIRUS A/17/TASMANIA/2020/151 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND FOR CHILDREN | 2023 |
|
RU2825672C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA A/17/DARWIN/2021/410 (H3N2) VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2023 |
|
RU2825673C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA A/17/MICHIGAN/2020/484 (H3N2) VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2023 |
|
RU2825583C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/VICTORIA/2019/276 (H1N1) PDM09 FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783878C1 |
